Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her-2 Negative Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02511639
What this trial is testing

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer Metastatic
Istituto Oncologico Veneto IRCCS 110
Large-scale testing (Phase 3)Study completedNCT04957212
What this trial is testing

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Cinnagen 214
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Large-scale testing (Phase 3)UnknownNCT04047758
What this trial is testing

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Who this might be right for
Breast Cancer
Shengjing Hospital 420
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07826052
What this trial is testing

Chemotherapy Exemption in Elderly Women With Node-Positive ER+/HER2- Breast Cancer

Who this might be right for
Breast CancerAdjuvant Therapy
Fudan University 494
Testing effectiveness (Phase 2)Active Not RecruitingNCT03414658
What this trial is testing

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Who this might be right for
Breast Cancer
Adrienne G. Waks 100
Early research (Phase 1)Looking for participantsNCT05996107
What this trial is testing

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
University of Michigan Rogel Cancer Center 30
Early research (Phase 1)WithdrawnNCT05905341
What this trial is testing

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Who this might be right for
Breast CancerOvarian CancerLiposarcoma+3 more
Pfizer
Testing effectiveness (Phase 2)Ended earlyNCT01891357
What this trial is testing

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Who this might be right for
Carcinoma, Ductal, Breast
Women's Cancer Study Group GmbH 64
Large-scale testing (Phase 3)Study completedNCT01275677
What this trial is testing

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Who this might be right for
HER2/Neu PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+6 more
National Cancer Institute (NCI) 3,270
Not applicableStudy completedNCT06686602
What this trial is testing

A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer

Who this might be right for
Advanced/Metastatic NSCLCAdvanced/Metastatic HER2-negative Breast Cancer
Daiichi Sankyo 13,759
Testing effectiveness (Phase 2)Study completedNCT03356860
What this trial is testing

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Who this might be right for
Breast CancerTriple Negative Breast CancerLuminal B
Grand Hôpital de Charleroi 57
Early research (Phase 1)Ended earlyNCT05622058
What this trial is testing

ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

Who this might be right for
Prevention of Chemotherapy-induced Myelosuppression
Aileron Therapeutics, Inc. 6
Testing effectiveness (Phase 2)Study completedNCT02061085
What this trial is testing

Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment

Who this might be right for
Breast NeoplasmMetastasis
MedSIR 53
Not applicableNot Yet RecruitingNCT06537674
What this trial is testing

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Who this might be right for
HER2+ Breast Cancer
Jiangsu Famous Medical Technology Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT00580112
What this trial is testing

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 127
Early research (Phase 1)WithdrawnNCT01320787
What this trial is testing

18-F-Fluoroacetate as PET Imaging Agent

Who this might be right for
Brain CancerBreast CancerProstate Cancer
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Ended earlyNCT00625898
What this trial is testing

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Who this might be right for
Breast Cancer
NSABP Foundation Inc 3,509
Not applicableLooking for participantsNCT06722612
What this trial is testing

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,916
Large-scale testing (Phase 3)Study completedNCT01619111
What this trial is testing

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Who this might be right for
HER2-negative Metastatic Breast CancerHER2-positive Circulating Tumor Cells
Prof. Wolfgang Janni 105
Next Page